Evidence map›Paper›PMID 38090644›Full record

ArticleVaccine: X2023

Hybrid immunity from SARS-CoV-2 infection and mRNA BNT162b2 vaccine among Thai school-aged children.

Kanchanok Saraban, Piyarat Suntarattiwong, Napaporn Chantasrisawad, Sophida Boonsathorn, Pope Kosalaraksa, Wanatpreeya Phongsamart, Auchara Tangsathapornpong, Peera Jaruampornpan, Suchada Srisarang, Thanyawee Puthanakit and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccine: X, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 7 institutions in 1 country.

Kanchanok SarabanQueen Sirikit National Institute of Child Health, Bangkok, Thailand.
Piyarat SuntarattiwongQueen Sirikit National Institute of Child Health, Bangkok, Thailand.
Napaporn ChantasrisawadDepartment of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
Sophida BoonsathornDepartment of Pediatrics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
Pope KosalaraksaPediatric Infectious Disease Unit, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.
Wanatpreeya PhongsamartDivision of Infectious Diseases, Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Auchara TangsathapornpongDivision of Infectious Diseases, Department of Pediatrics, Faculty of Medicine, Thammasat University, Pathum Thani, Thailand.
Peera JaruampornpanVirology and Cell Technology Research Team, National Center for Genetic Engineering and Biotechnology (BIOTEC), National Science and Technology Development Agency (NSTDA), Pathum Thani, Thailand.
Suchada SrisarangQueen Sirikit National Institute of Child Health, Bangkok, Thailand.
Thanyawee PuthanakitDepartment of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
KIDSVAX study team
Queen Sirikit National Institute of Child Health · THChulalongkorn University · THKhon Kaen University · THMahidol University · THNational Science and Technology Development Agency · THSiriraj Hospital · THThammasat University · TH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: To compare the immune response of hybrid immunity - arising from SARS-CoV-2 infection and mRNA BNT162b2 vaccination - to that of 2-doses of vaccine. Methods: In a subanalysis of BNT162b2 vaccine trial in 5 to 11-year-old children, There were 179 children who had hybrid immunity compared with 134 children with solely 2-dose vaccine. The immunological outcome was a surrogate virus neutralization test (sVNT) against the Omicron strain, BA.1, (%inhibition). An sVNT level ≥68 % inhibition was considered as protective immune response. Results: From February to April 2022, 179 children had COVID-19 natural infection resulting in hybrid immunity included: Group1;prior vaccination(n = 17), Group2;after the first dose(n = 61), and Group3;after the second dose(n = 97). The proportion of children with protective immune response was higher in Group 3 and Group 1 - 61.9 % and 58.8 %, compared to 36.1 % and 34.3 % in Group 2 and comparator group (2 doses of vaccine), respectively. The geometric mean % inhibition of sVNT was higher in Group 1 (68.5, 95 %CI 55.5-84.6) and Group 3 (63.5, 95 %CI 55.5-72.6), followed by comparator group (49.6, 95 %CI 44.8-54.9) and Group 2 (42.1, 95 %CI 34.6-51.3), p < 0.001. Conclusions: Immune response that arises from BNT162b2 vaccine after natural infection and infection after 2 doses of BNT162b2 was higher than infection after partially-vaccinated children.

Indexed as

BNT162b2Hybrid immunityNeutralizing antibodyOmicron variantSARS-CoV-2School-aged children

Identifiers

PMID38090644
PMCPMC10714229
OpenAlexW4388980289

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.